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PI3KThe last decades have witnessed an exponential increase in our knowledge of Rho GTPase signaling network
which further highlighted the cross talk between these proteins and the complexity of their signaling path-
ways. In this review, we summarize the upstream and downstream players from Rho GTPases that are mainly
involved in actin polymerization leading to cell motility and potentially playing a role in cancer cell
metastasis.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1955
2. Rho GTPases: General properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1956
3. Signaling pathways upstream Rho GTPases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1957
4. Activation of Rho GTPases by adhesion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1958
5. Effectors of Rho GTPases in actin polymerization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1958
6. Role in cell motility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1959
7. Adhesion formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1959
8. Cell body contraction and tail retraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1959
9. Crosstalk between Rho GTPases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1960
10. Altered role in cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1960
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19611. Introduction
Cell motility is an essential cellular process involved in numerous
physiological events including embryogenesis, wound healing, in-
ﬂammation and tissue regeneration. It is a central process for cancer
cell invasion and metastasis. Cell migration usually occurs in response
to a chemoattractant or a growth factor present around the cell, aSciences, Lebanese American
eirut, Lebanon. Tel.: +961 1
i).
nc. Open access under CC BY-NC-ND liprocess known as chemotaxis. A great effort in research has been
directed towards understanding the molecular basis of cell motility
in an attempt to ﬁnd novel therapeutic targets that would inhibit
tumor growth and metastasis [1]. Once a signal is detected, a migrat-
ing cell enters the cell motility cycle in an amoeboid-like manner.
This starts with determining the direction of motion towards the
chemoattractant. Then the cell extends a protrusion, towards the
direction of motion, by initiating the polymerization of new actin ﬁl-
aments [2]. The actin-rich protrusion then needs to be stabilized by
the formation of adhesions to the cell substratum. This provides an-
chorage to the cell to transmit a mechanical force used to pull its
cell body forward towards the direction of motion. Simultaneously,
the adhesion structures at the rear end of the cell are disassembled
and the cell retracts its tail and moves forward [3,4,2]. Motility is
largely dependent on localized actin polymerization at the leadingcense. 
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tures in the lamellipodia and are intrinsically polarized with a slow
growing or pointed end decorated with myosin and the fast growing
end or the barbed end. Actin monomer addition at the barbed end is
highly favored. At the fast-growing end, ATP-actin monomers bind
with a rate constant that is 10-fold higher than the rate of monomer
binding at the pointed end. Barbed ends are oriented outwards with
respect to cell surface. The rate limiting steps for actin polymerization
in vivo are the availability of free barbed ends and the availability of
free actin monomers for ﬁlament elongation [7]. Three mechanisms
lead to the generation of free barbed ends and these consist of
uncapping, severing and de novo nucleation [8,9]. Coﬁlin generates
free barbed ends through the severing of actin ﬁlaments, leading to
actin nucleation [10]. Severing involves the cooperative activity of
two coﬁlin molecules that bind directly to the actin ﬁlament, intro-
ducing a tilt of approximately 12° that twists the ﬁlament and results
in its breakage [11]. The need for severing to elongate actin ﬁlaments
might seem counterintuitive, but severing is needed to expose free
barbed ends since most ﬁlaments in resting cells are capped. Coﬁlin
was found to localize to the extreme leading edge in ﬁbroblasts
and carcinoma cells [1] where actin polymerization occurs [12–14]. In
carcinoma cells, the kinetics of coﬁlin activation coincides with the ki-
netics of barbed end formation, and the microinjection of a function-
blocking antibody against coﬁlin inhibited barbed end production in
the nucleation zone [15,13]. Coﬁlin-dependent actin polymerization
during cell motility is pH-dependent. Coﬁlin activity is also regulated
through phosphorylation at Ser-3 by LIM-kinases (LIMK1 and LIMK2).
Coﬁlin is positively regulated throughdephosphorylation by the activity
of PP2A and the Slingshot family of phosphatases [16–18]. In carcinoma
cells, however, over-expressing S3A-coﬁlinmutant fails to stimulate the
generation of barbed ends in resting cells [19]. In addition, in response
to EGF stimulation, the increase in coﬁlin severing activity coincided
with an increase in the levels of phosphorylated coﬁlin in the cells
[20]. This indicates that, in carcinoma cells, dephosphorylation is not
themain regulatorymechanism leading to the activation of coﬁlin in re-
sponse to EGF stimulation. In addition to the regulation by pH and LIMK,
coﬁlin is kept inactive in resting cells through binding to PI(4,5)P2 at the
cell membrane [21]. This inhibition through binding is proposed to be
alleviated through the hydrolysis of PIP2 by PLCγ. Indeed, high resolu-
tion ﬂuorescence microscopy staining for PIP2 and coﬁlin localization
revealed that inhibition of PLCγ blocked the dissociation of coﬁlin
from PIP2 in the membrane. Also the inhibition of PLCγ led to the inhi-
bition of coﬁlin severing activity and coﬁlin-dependent barbed ends
production in carcinoma cells [22,23]. These studies indicate that PLCγ
is the main regulator of coﬁlin activity in carcinoma cells [16]. De
novo nucleation is the third mechanism through which barbed ends
can be generated and this is mediated by the Arp2/3 complex [24,9].
Arp2/3 complex is a stable assembly of seven highly conserved sub-
units, of which two are actin-related proteins (Arp2 and Arp3) that pro-
vide a template for actin nucleation. Electron microscopic analysis
revealed that actin ﬁlaments at the leading edge are highly branched
with a predominant 70° angle. This conﬁguration contributes to theme-
chanical protrusive power needed in the lamellipodia. Arp2/3 nucleates
actin by creating daughter ﬁlaments at an angular branch of 70° from
pre-existing mother ﬁlaments, and Arp2/3 is localized at the pointed
end of the Y junctions formed by themother and the daughterﬁlaments
[12]. Arp2/3 is activated by the WASP/SCAR/WAVE family of scaffold
proteins, which are key regulators of actin polymerization that are acti-
vated by Rho GTPases [25].
2. Rho GTPases: General properties
Numerous intracellular proteins are involved in the regulation of the
cell motility cycle. One of the most important familie of proteins regu-
lating this process is the Rho family GTPases. Members of this family
play a crucial role in the reorganization of the actin cytoskeleton[9,26]. Members of the Rho-family GTPases are small GTP-binding pro-
teins (GTPases) that range between 20 and 40 KDa in size. The Ras gene
was ﬁrst discovered as the v-Ras oncogene of the Rous sarcoma virus
around 1980 [27]. The Ras superfamily contains more than 130 mem-
bers, which fall into the Ras, Rho, Arf/Sar1 and Rab/Ran-subfamilies
[27,5]. The Rho gene was discovered as a homolog of the Ras gene in
Aplysia in 1985. Rho family-GTPases include 23 members divided into
six subgroups. Rho homologues, RhoA, RhoB and RhoC which were dis-
covered in mammalian cells [28]. Other members of the Rho-subfamily
were later identiﬁed, including human Cdc42 and Rac1 and Rac2, which
were found to be distinct in function from the other Rho proteins but
share signiﬁcant homology in amino acid sequence [29,30,6]. These pro-
teins play a vital role in cancer cell motility. All aspects of cellularmotil-
ity and invasion including cellular polarity, cytoskeletal re-organization,
and signal transduction pathways are controlled through the interplay
between the Rho-GTPases [31,5]. Activated Rho proteins can bind effec-
tor proteins and modulate cell behavior and morphology. Rho GTPases
are implicated in cell migration through their ability to organize and
regulate actin-containing structures. Frequent studies have shown
that the Rho family GTPases regulate cell motility in breast cancer
through their ability to mediate the remodeling of actin cytoskeleton
as well as translating cellular signals from plasmamembrane receptors
to regulate focal adhesion, cell polarity, vesicular trafﬁcking and gene
expression [5]. All Rho GTPases have a consensus amino acid sequence
at the N-terminal half that is responsible for speciﬁc interaction with
GDP and GTP molecules and for a GTPase activity that hydrolyzes
bound GTP into GDP and Pi.. Four important domains are implicated in
the binding and hydrolysis of GTP (Fig. 1A) [32]. One of themost impor-
tant domains is the effector or switch I domain, which is required for
downstream functions of Rho GTPases. Rho proteins also have se-
quences at their COOH termini that undergo post-translational modiﬁ-
cations with lipids, such as farnesyl, geranylgeranyl, palmitoyl and
methyl moieties, and that are necessary for proper localization in the
cell [33].
Rho GTPases switch between two conformations, a GDP-bound in-
active state where they are sequestered and kept in the cytoplasm;
and an active GTP-bound state [31,34]. Since Rho GTPases control
many important signal transduction pathways, their activation is tightly
regulated in the cell. The activity of Rho GTPases is regulated by nucle-
otide binding and by subcellular localization [35]. In response to a cer-
tain signal, replacing the bound GDP with a GTP molecule activates
Rho GTPases. This induces a conformational change favoring the bind-
ing of the active Rho protein to downstream effectors. After activation
of the effector, the GTP molecule is hydrolyzed to GDP rendering the
GTPase back to its inactive form [36,5]. This constitutes a single cycle
of activation/inactivation of Rho GTPases. Rho GTPases mediate the
transduction of numerous intracellular signaling pathways affecting
cell behavior andmorphology. Thus, these critical proteins are implicat-
ed in many essential cellular processes including actin dynamics, gene
transcription, cell cycle progression, cell adhesion,motility and invasion
[37,5]. Rho GTPases act as molecular switches that relay extracellular
signals and translate them into intracellular events through their down-
stream effectors [34]. Since Rho GTPases control many important signal
transduction pathways, their activation is tightly regulated in the cell.
The activity of Rho GTPases is regulated by nucleotide binding and
by subcellular localization [38,34,35]. Rho GTPases are found in two
forms, a GDP-bound inactive and a GTP-bound active form. An up-
stream signal stimulates the dissociation of GDP and the binding of
GTP. This leads to the conformational change of the effector-binding
region of the GTPase so that this region interacts with downstream
effectors. The GTP-bound form is then converted to the GDP-bound
form releasing the bound effector. This constitutes a single cycle of
activation/inactivation of Rho GTPases (Fig. 2B) [38]. The switch
between active GTP-bound and inactive GDP-bound state is regulated
by Guanine nucleotide exchange factors (GEFs), GTPase-activating pro-
teins (GAPs) and Guanine-nucleotide dissociation inhibitors (GDIs).
Fig. 1. Rho GTPases and downstream effectors. A) General structural domains of Rho GTPases include effector binding domains switch I and switch II, also important for GTP/GDP
binding and interaction with upstream regulators. B) Downstream targets of Rho include the serine/threonine kinase ROCK which is mainly involved in the formation of stress ﬁbers
and focal adhesions. ROCK phosphorylates downstream myosin light chain (MLC) leading to actin–myosin contractility. At the same time, ROCK inhibits MLC dephosphorylation by
inhibiting MLC phosphatases via their myosin binding subunit (MBS). The mammalian homolog of diaphanous (mDia) is another important Rho effector mediating actin nucleation.
LIMK is also another downstream effector of Rho, which phosphorylates the actin severing protein coﬁlin inhibiting its severing activity and production of barbed ends. Down-
stream signaling of Cdc42 and Rac includes scaffold proteins belonging to the WASP/SCAR/WAVE family, key regulators of actin nucleation and polymerization. p21 activating
kinase (PAK) is a common effector protein of both Rac and Cdc42. Active PAK phosphorylates MLCK thereby inactivating it and inhibiting MLC phosphorylation and contractility.
PAK also phosphorylates and activates LIMK which potentially results in the phosphorylation of coﬁlin inhibiting its actin-severing function.
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such as Src homology 3 (SH3) and pleckstrin homology domain (PH)
(Fig. 2A). These regulators interact with phospholipids of the cell mem-
brane and other proteins modulating the GDP–GTP exchange activity
[5]. During nucleotide exchange, the initial dissociation of GDP from
the inactive form of Rho GTPases is considered the rate-limiting step.
This reaction is very slow and is stimulated by a guanine nucleotide ex-
change factors (GEFs). Thus, GEFs activate Rho GTPases by mediating
the exchange of GDP to GTP [38,39]. Rho GTPases are negatively regu-
lated by Rho GTPases activating proteins (GAPs). These proteins inhibit
Rho GTPases by activating their intrinsic GTPase activity. This leads to
the hydrolysis of the bound GTP into GDP converting Rho GTPases
back to their inactive conformation [40]. In addition to activating GTP
hydrolysis, GAPs may function as effectors of Rho GTPases to mediate
other downstream effector functions [38,5]. Guanine nucleotide disso-
ciation inhibitors (GDIs) block both the GDP/GTP exchange and the
GTP hydrolysis. These proteins prevent the dissociation of GDP fromthe inactive Rho proteins and their interaction with downstream effec-
tors. GDIs can also bind to the active GTP-bound form preventing their
interaction with GAPs. Moreover, GDIs modulate the cycling of GTPases
between the cellmembrane and the cytoplasm. Since the activity of Rho
GTPases crucially depends on their translocation to the cell membrane,
GDIs are considered important regulators with the ability to sequester
GTPases in the cytoplasm by masking their hydrophobic region/
domains [41,42].
3. Signaling pathways upstream Rho GTPases
Rho family GTPases are activated in response to numerous extra-
cellular stimuli captured by plasma membrane receptors. Hence,
these proteins are involved in translating signals to regulate various
cellular functions including cytoskeleton re-organization, cell–cell
interaction, proliferation, cell adhesion, polarity, chemotaxis and
many others [31,5]. Rho GTPase-activating protein GEFs contain the
Fig. 2. Regulation of Rho GTPases. A) The GEF module consists of the DH–PH minimum structure. B) In response to external stimulus through receptor tyrosine kinases (RTKs), PI3K
produces PIP3 which recruits Rho GEFs. This promotes the GTP nucleotide exchange. GAPs inactivate Rho GTPases by stimulating the intrinsic GTPase activity leading to the
GDP-bound inactive form of Rho. Rho GTPases are kept inactive by being sequestered by GDIs in the cytosol.
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that has a high binding afﬁnity to phosphoinositides and can affect
the catalytic DH domain of GEFs [43]. Binding to PI(4,5)P2 of the plas-
ma membrane favors the interaction between PH domain of GEFs and
the catalytic DH domain inhibiting its activity (Fig. 2). PI3K phosphor-
ylates PI(4,5)P2 producing PI(3,4,5)P3 that has high afﬁnity to PH do-
main, thus releasing the DH domain and activating GEFs. In turn, GEFs
can bind and activate Rho GTPases [39]. External stimuli such as LPA,
PDGF, EGF and insulin have been shown to trigger the activation of
Rho GTPases in a PI3K dependent manner (Fig. 2B). Treatment of ﬁ-
broblasts with wortmannin, a PI3K inhibitor, inhibited Rho and Rac
mediated membrane rufﬂing in response to EGF [44]. These data sug-
gest that PI3K acts upstream of Rho GTPases to stimulate membrane
rufﬂing in response to growth factors. A well-characterized nucleo-
tide exchanger, Vav, is known to be activated by PI3K. Vav is phos-
phorylated on tyrosine residues in the N-terminal region by Src and
Syk kinases leading to the activation of its catalytic activity [45]. An
autoinhibitory constraint is imposed by its PH domain. However,
when bound to PI(3,4,5)P3 produced by PI3K, the PH/DH interaction
is weakened and this alleviates the inhibition. The PH domain of
Son of svenless (Sos) also binds to PIP3 relieving intramolecular inhi-
bition. Sos is a GEF for both Ras and Rac. It forms a complex with a
number of adaptor proteins downstream of receptor tyrosine kinases
[46,47]. Therefore, the activity of Rho GTPases is spatially regulated in
many cellular functions following the subcellular localization of GEFs.
PI3K activation plays an essential role in regulating the localization of
GEFs through the production of PIP3 which binds to the PH domain of
GEFs. Deletion of the PH domain in many GEFs results in the loss of in
vitro activity, which can be restored by the addition of a CAAXmotif that
targets the protein to the plasmamembrane [48]. In addition, many stud-
ies in mammary tumors have shown that PI3K acts downstream of Racand Cdc42 [49]. These ﬁndings suggest that PI3K and Rho GTPases are in-
volved in a positive feedback loop that stimulates lamellipodia formation
during cell motility.
4. Activation of Rho GTPases by adhesion
Numerous signaling pathways involving Rho GTPases are activat-
ed downstream of the cell adhesion to the ECM [50]. In this respect,
the activation of focal adhesion kinase (FAK) leads to the phosphory-
lation and activation of p130cas and paxillin [51,50]. Phosphorylated
p130cas activates Rac by forming a complex with adaptor proteins
Crk and DOCK180, which is a GEF for Rac [52,53]. Paxillin also forms
a multi-component complex with the protein PKL and PIX, the latter
being another Rac GEF. In addition to activating Rac, FAK also acti-
vates p190RhoGAP thus leading to the inhibition of RhoA. In many
cells, during initial cell adhesion, FAK activity stimulates high Rac
activity and low RhoA activity [54] [2].
5. Effectors of Rho GTPases in actin polymerization
The major function of Rho GTPases is to regulate actin polymeriza-
tion required for a myriad of biological processes [38]. The effects of
Rho, Rac and Cdc42 on actin were initially postulated using quiescent
Swiss3T3 ﬁbroblasts and dominant active or negative GTPase mu-
tants. Addition of a stimulus, lysophosphatidic acid (LPA) induced
the formation of contractile actin–myosin stress ﬁbers and focal adhe-
sions that associate with the tip of stress ﬁbers. This process was
blocked by C3 transferase, and implicated a role of Rho in stress
ﬁber formation [6]. Growth factors, such as platelet-derived growth
factor (PDGF), insulin or epidermal growth factor (EGF) induced the
formation of protrusive structures, such as lamellipodia and membrane
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response [30]. Bradykinin induced the formation of microspikes and
ﬁlopodia and the dominant negative [Asn17] Cdc42 inhibited this re-
sponse [55]. Based on these original studies, it was concluded that
Rho, Rac and Cdc42 regulate the assembly of actin–myosin ﬁlaments,
lamellipodia and ﬁlopodia, respectively [56]. Rho GTPase effectors, as
previously mentioned, interact with the GTP-bound active form of
Rho GTPases. Comparisons of the crystal structure of the GDP-bound
form and the [Val14]-Rho GTPase–GTP form (in Ras, RhoA, Cdc42 and
Rac), revealed that the conformational differences between the GDP
and the GTP-bound forms are restricted to two surface loops, named
switch I (the effector domain) and switch II (Fig. 1A). The effector do-
main forms an extended β2-strand/loop structure. This extended struc-
ture makes it possible for different effectors and regulators to bind to
different subdomains of the effector domain at the same time. Alterna-
tively, binding to an effector at this domain might interfere with
the binding of another effector/regulator at this domain (in another
subdomain), providing a basis for the regulation of different processes
downstream of Rho GTPases [57]. Numerous mutations have been
introduced into the effector domain of Rho, Rac and Cdc42 and this
prevented the binding of some target proteins. For example, the interac-
tion of PAK (p21-activated kinase) with Cdc42/Rac could potentially be
blocked or reduced by various mutations [58,59]. Effectors of Rho
GTPases have multiple domains that play an additional role in regulat-
ing their activity. This includes a PH domain in N-WASP, WASP and
ROCK, which promotes association with the membrane, where active
Rho GTPases are present. [25]. WASP and PAK contain proline-rich
SH3-bindingmotifs which bind to the adaptor Nck that in turn contains
an SH2 domain and recruits these effectors to activated receptor tyro-
sine kinases. Many Rho GTPase effectors also contain coiled-coil regions
(l which plays a role in protein–protein oligomerization [56].
Downstream targets of Rho include the serine/threonine kinase
p160ROCK which is mainly involved in the formation of stress ﬁbers
and focal adhesions (Fig. 1B) [60,61]. ROCK is known to phosphorylate
myosin light chain (MLC) leading to actin–myosin contractility. At the
same time, ROCK inhibits MLC dephosphorylation by inhibiting MLC
phosphatases via their myosin binding subunit (MBS) [62]. However,
normal stress ﬁber formation also requires the activity the mammalian
homolog of diaphanous (mDia), another important Rho effector medi-
ating actin nucleation. LIMK is another downstream effector of Rho,
which phosphorylates and inhibits the actin severing protein coﬁlin
[63]. However, a recent study showed that RhoC in particular is respon-
sible for the phosphorylation of coﬁlin in a spatiotemporal restriction
in invadopodial protrusions [64]. Other Rho effectors include members
of the ezrin–radixin–moesin (ERM) proteins. These proteins are found
to associate with the cell plasma membrane where they mediate
Rho-dependent actin cytoskeleton remodeling [5]. Downstream signal-
ing of Cdc42 and Rac includes scaffold proteins belonging to theWASP/
SCAR/WAVE family containing the VCA domain (Fig. 1B) [49,5]. These
are key regulators of actin nucleation protein Arp2/3 complex that stim-
ulates actin polymerization at the leading edge of the cell [37,24]. Some
proteins are target effectors of both Rac and Cdc42. One of these pro-
teins is the serine/threonine p21 activating kinase (PAK). PAK isoforms
have an N-terminal regulatory domain and a C-terminal catalytic do-
main. Moreover, all PAK proteins share a common domain responsible
for interaction with Rac and Cdc42, referred to as Cdc42/Rac interactive
binding (CRIB) domain. Binding of active GTPase disrupts the auto-
inhibitory conformation of PAK and activates its catalytic domain by phos-
phorylation [65,59,54]. Active PAK phosphorylates MLCK thereby
inactivating it and inhibiting MLC phosphorylation and contractility
[66,67]. PAK is also targeted to adhesion complexes regulating focal adhe-
sion turnover. In addition, PAK phosphorylates and activates LIMK [68].
LIMK is therefore activated throughROCKandPAKpathways downstream
of Rho and Cdc42/Rac respectively (Fig. 1B). Moreover, in MTLn3 cells,
Cdc42 has been shown to mediate the translocation of both N-WASP
andWAVE2 to the leading edge in response to EGF stimulation [71].6. Role in cell motility
In general, cell migration can be divided into separate successive
steps: determining the direction of motion, cell polarization,
lamellipodial protrusion, adhesion formation followed by cell body
contraction and tail retraction (Fig. 3) [1]. The initial step during cell
migration is the determination of direction of motion by generating
membrane protrusions. These protrusions can be either spike-like
ﬁlopodia or larger, broad lamellipodia [5]. Filopodia are classically
regarded as sensors for chemotactic cues required for direction sens-
ing during cell migration. These protrusions extend out from the cell
detecting and transmitting any environmental changes [69]. Cdc42
regulates the formation of ﬁlopodia by initiating actin polymerization
through the activation of N-WASP [44]. The lamellipodium is a mesh-
work of highly branched actin ﬁlaments at the cell edge [70]. The
structure of the lamellipodia is known to be Rac-dependent involving
a number of Rac downstream effectors such as severing proteins ADF/
coﬁlin and actin binding proteins like the Arp2/3 complex that is
responsible for actin nucleation and branching [18]. This is in addition
to the activation of PIP-5 kinase that produces PIP2 inhibiting actin-
capping proteins. However these effectors are also downstream of
Cdc42 (Fig. 1B). Consequently, Cdc42 is regarded as a potential regu-
lator that drives Rac-dependent lamellipodia [71]. In addition to its
role in actin regulation, Cdc42 plays a crucial role in deﬁning cell po-
larity with respect to the direction of motility, through the regulation
of the microtubule cytoskeleton [32].
7. Adhesion formation
Extended protrusions of migrating cells need to be stabilized by ad-
hering to the ECM. Cell adhesion to the ECM activates Rac and Cdc42,
which is required for cell spreading [72]. It is therefore possible that
there is continuous formation of new interactions between integrins
and the ECM. The speed of cell migration depends on the composition
of the substratum that dictates the relative levels of active Rho, Rac
and Cdc42. Thus, a constant crosstalk between integrins and Rac is
decisive for the cellular response to changing ECM composition. Rac
stimulates the assembly of small punctate structures known as focal
complexes that formbehind the leading lamellipodiumof the cell. How-
ever, these structures do not transmit adequate contractility during cell
motility [73]. Rac induces focal complex formation directly, through ac-
tivating PAK, which in turn interacts with a complex of the exchange
factor PIX, paxillin and GIT family of proteins. Also, Rac can indirectly
contribute to the formation of focal complexes through antagonizing
Rho activation. As the cell moves in the direction of motion, focal com-
plexes can either disassemble or mature into larger andmore stabilized
Rho-dependent structures known as focal adhesions [74,69]. Focal ad-
hesions provide anchorage for the cell thus conferring mechanical
strength needed for the cell to contract its cell body and slide along
the ECM. Therefore, cell migration requires the focal complex/adhesion
turn over regulated by the interplay between Rac and RhoA. Increasing
Rho activation stabilizes focal adhesion attachments to the ECM, hence
inhibiting cell motility [75,66,76].
8. Cell body contraction and tail retraction
In a migrating cell, adhesion to the ECM alone is not sufﬁcient. Cell
body contractility and tail retraction are needed for the completion of
the cell motility cycle. Cell body contraction depends on actomyosin
contractility, which is directly regulated by Rho. Rho acts via ROCK
inducing contractility through the phosphorylation of MLC (Fig. 1B).
This results in transmission of tension to the sites of adhesion. MLC
is also regulated by MLC kinase (MLCK), thus it is likely that ROCK
and MLCK act in concert to control cell contractility [5]. In addition
to the ROCK pathway, RhoA is believed to negatively regulate coﬁlin
leading to the inhibition of cell protrusions [77]. Thus, RhoA localizes
Fig. 3. Rho GTPases in the cell motility cycle. A migratory cell enters the cell motility cycle in response to a chemoattractant signal. Cdc42 determines the direction of motion. Rac
induces the formation of actin-rich lamellopodial protrusion at the leading edge. New protrusion is stabilized by the formation of new adhesions to the underlying substratum, a
process controlled mainly by Rac and RhoA [77]. Rho acts at the rear end leading to the formation of stress ﬁbers and actin–myosin contractility providing tension for the cell to
retract its tail and move forward.
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retraction is the ﬁnal step of cell migration. At this point, adhesions
must disassemble to ensure the completion of the cell motility cycle
[78]. Although the mechanism of tail detachment depends on the
cell type and the strength of adhesion to the ECM, it is known that
the reduction in RhoA activity could potentially inhibit retraction
through reduced actomyosin contractility [79,77]. Therefore, the con-
tinuous interplay between Rho GTPases govern all aspects of cell mo-
tility including cell polarity, cytoskeleton re-organization, adhesion
formation, cell contraction and tail retraction (Fig. 3) [44,34].9. Crosstalk between Rho GTPases
It was initially believed that Rho, Rac and Cdc42 play a deﬁned
role in regulating actin and adhesion dynamics during cell motility.
However, this model is considered too simplistic due to crosstalk
between the signaling pathways regulated by Rho GTPases [80,81]. It
was shown that RhoA for instance, is not only restricted to the genera-
tion of contractile force at the rear end of the cell, but also coordinateswith Rac and Cdc42 at the cell edge in regulating actin cytoskeleton
[77]. Other studies have revealed an inverse relationship between Rho
and Rac, where activation of Rac leads to the inactivation of Rho and
vice versa [82]. This antagonism is explained in their antagonistic func-
tions in cell adhesion. Other examples where one familymember nega-
tively affects the activity of the other is through stimulating a GAP, or
positively activating another through stimulating a GEF [83]. Recent
studies showed that distinct roles in migration and invasion could be
implemented by different isoforms of Rho particularly RhoA and
RhoC. This could be by acting through different targets [84].10. Altered role in cancer
The acquisition ofmotile and invasive phenotypes is the key compo-
nent in developing metastatic competence. Both of these processes are
strictly regulated by members of the Rho family GTPases [31]. Studies
have shown that constitutively activated Rho GTPases lead to the trans-
formation of ﬁbroblasts. In addition, genetic screening showed that
Rho GTPases, particularly RhoA and RhoC, are found to be either
1961S. Hanna, M. El-Sibai / Cellular Signalling 25 (2013) 1955–1961overexpressed or hyperactive in many tumors including breast cancer
[31,5].Moreover, overexpression of RhoCwas associatedwith 32% of in-
vasive breast cancer and invasive ductal carcinoma [26]. In fact, forced
expression of Rho proteins induced malignant transformation of
human mammary epithelial cells resulting in an aggressive and highly
motile phenotype. In addition, expressing a dominant-negative form
of Rho inhibited cellular motility [85]. Therefore, aberrant expression
of Rho GTPases primarily contributes to cell transformation and tumor
development, given their role in the regulation of actin polymerization
andmotility and their interactionwith numerous signaling pathways in
addition to regulating extracellular matrix remodeling [86,87]. Domi-
nant inhibitory or activating approaches have been used to describe
the role of Rho GTPases in primary tumor growth and metastasis. Reg-
ulatory proteins GEFs and GAPs can cause dysfunctional activation/
inhibition of Rho GTPases affecting cellular motility, invasion and
ultimately metastasis [26,82,86]. Moreover, as Rho GTPases are highly
involved in promoting cellular transformation, many downstream
effectors could be directly involved in tumor formation. For instance,
direct inhibition of RhoA, through microinjection of C3T, or inhibiting
its downstream effector ROCK using Y27632 leads to decreasedmotility
and inhibition of focal complex maturation into focal adhesions [77].
There is also evidence that aberrant activation of Rho proteins can con-
tribute to prolonged survival and prevent apoptosis. This is because of
the ability of Rho GTPases to affect CDKs involved in regulating cell
cycle progression promoting tumor initiation and growth [88]. Cyclin
D1 is found to be overexpressed in 50% of breast cancers. Rho GTPases
correlate to high expression of cyclin D1 through the activation of its
promoter. Rac1 regulates a variety of signaling pathways implicated
in malignant phenotype. Typically, Rac1 affects transcription of cyclin
D1 through the activation of NF-κB and ATF-2 transcription factors
that bind and activate cyclin D1 promoter. Thus, constitutively active
forms of Rac1 stimulated transformation potential and cell proliferation
through cyclin D1 overexpression. Moreover, the use of pharmacologic
inhibitor NSC23766 selectively inhibits Rac1 and leads to the suppres-
sion of cell growth in breast cancer cell lines [89]. Furthermore, RhoA
overexpression inhibits p21, a cyclin-dependent kinase inhibitor and
an important tumor suppressor gene product [90]. Given their integra-
tion in various pathways involved in cancer, Rho GTPase and their reg-
ulators are considered important therapeutic targets through the
inhibition of cancer cell proliferation, motility and invasion. Several
drugs have been shown to abrogate Rho GTPase functions. These
drugs could directly target Rho proteins such as farsenalytrasferase in-
hibitors (FTIs) and strongylophorine-26 or could act through inhibition
of their downstream effectors such as ROCK inhibitor Y-27632 [91–93].
References
[1] D.a. Lauffenburger, a.F. Horwitz, Cell 84 (1996) 359–369.
[2] M. Bailly, et al., Microscopy Research and Technique 43 (1998) 433–443.
[3] R. Ananthakrishnan, A. Ehrlicher, International Journal of Biological Sciences 3
(2007) 303–317.
[4] J.S. Condeelis, et al., Seminars in Cancer Biology 11 (2001) 119–128.
[5] Y. Tang, et al., Frontiers in Bioscience 13 (2008) 759–776.
[6] a.J. Ridley, a. Hall, Cell 70 (1992) 389–399.
[7] A. Ponti, et al., Science (New York, N.Y.) 305 (2004) 1782–1786.
[8] R.J. Eddy, et al., The Journal of Cell Biology 139 (1997) 1243–1253.
[9] J. Condeelis, Trends in Cell Biology 11 (2001) 288–293.
[10] I. Ichetovkin, et al., Cell Motility and the Cytoskeleton 45 (2000) 293–306.
[11] V.E. Galkin, et al., The Journal of Cell Biology 153 (2001) 75–86.
[12] T.M. Svitkina, G.G. Borisy, The Journal of Cell Biology 145 (1999) 1009–1026.
[13] a.Y. Chan, et al., The Journal of Cell Biology 148 (2000) 531–542.
[14] M. Bailly, et al., The Journal of Cell Biology 145 (1999) 331–345.
[15] V. DesMarais, et al., 117 (2006) 3499–3510.
[16] M. Oser, J. Condeelis, Journal of Cellular Biochemistry 108 (2009) 1252–1262.
[17] B.W. Bernstein, J.R. Bamburg, Trends in Cell Biology 20 (2010) 187–195.
[18] M. Van Troys, et al., European Journal of Cell Biology 87 (2008) 649–667.
[19] N. Zebda, et al., 151 (2000).
[20] N. Tania, et al., Biophysical Journal 100 (2011) 1883–1892.[21] H. Zhao, et al., Biophysical Journal 98 (2010) 2327–2336.
[22] G. Mouneimne, et al., The Journal of Cell Biology 166 (2004) 697–708.
[23] N. Yonezawa, et al., The Journal of Biological Chemistry 266 (1991) 17218–17221.
[24] K.G. Campellone, K.G. Welch, Nature Reviews. Molecular Cell Biology 11 (2010)
237–251.
[25] T. Takenawa, H. Miki, Journal of Cell Science 114 (2001) 1801–1809.
[26] K.L. Van Golen, Breast Cancer Research: BCR 5 (2003) 174–179.
[27] Y. Takai, et al., Physiological Reviews 81 (2001) 153–208.
[28] P. Madaule, R. Axel, Cell 41 (1985) 31–40.
[29] K. Shinjo, et al., Proceedings of the National Academy of Sciences of the United
States of America 87 (1990) 9853–9857.
[30] a.J. Ridley, et al., Cell 70 (1992) 401–410.
[31] E. Sahai, C.J. Marshall, Nature Reviews. Cancer 2 (2002) 133–142.
[32] D.I. Johnson, 63 (1999).
[33] A. Magee, et al., Biochemical Society Transactions 20 (1992) 497–499.
[34] F.M. Vega, A.J. Ridley, FEBS Letters 582 (2008) 2093–2101.
[35] K. Wennerberg, C.J. Der, Journal of Cell Science 117 (2004) 1301–1312.
[36] S. Etienne-Manneville, A. Hall, Nature 420 (2002) 629–635.
[37] A.B. Jaffe, A.Hall, Annual ReviewofCell andDevelopmental Biology21 (2005) 247–269.
[38] F. Grise, et al., Biochimica et Biophysica Acta 1795 (2009) 137–151.
[39] A. Schmidt, A. Hall, Genes & Development 16 (2002) 1587–1609.
[40] S.Y. Moon, Y. Zheng, Trends in Cell Biology 13 (2003) 13–22.
[41] C. DerMardirossian, G.M. Bokoch, Trends in Cell Biology 15 (2005) 356–363.
[42] R. Garcia-Mata, et al., Nature Reviews. Molecular Cell Biology 12 (2011) 493–504.
[43] M. Macias, et al., Nature 369 (1994) 675–677.
[44] C.D. Nobes, et al., Journal of Cell Science 108 (Pt 1) (1995) 225–233.
[45] M. López-lago, et al., Tyrosine Phosphorylation Mediates Both Activation and
Downmodulation of the Biological Activity of Vav, 2000, http://dx.doi.org/10.1128/
MCB.20.5.1678-1691.2000, (Updated).
[46] B. Das, et al., The Journal of Biological Chemistry 275 (2000) 15074–15081.
[47] G. Scita, et al., 401 (1999) 8–11.
[48] I.P. Whitehead, et al., Molecular and Cellular Biology 19 (1999) 7759–7770.
[49] P.J. Keely, et al., Nature 390 (1997) 632–636.
[50] K.a. DeMali, K. Burridge, Journal of Cell Science 116 (2003) 2389–2397.
[51] E. Zamir, B. Geiger, Journal of Cell Science 114 (2001) 3583–3590.
[52] W.H. Goldmann, Cell Biology International 36 (2012) 649–652.
[53] Y. Wang, M.a. McNiven, The Journal of Cell Biology 196 (2012) 375–385.
[54] T. Davies, J.C. Canman, The Journal of Cell Biology 198 (2012) 769–771.
[55] R. Kozma, et al., Molecular and Cellular Biology 15 (1995) 1942–1952.
[56] a.L. Bishop, a. Hall, The Biochemical Journal 348 (Pt 2) (2000) 241–255.
[57] C. Jobichen, et al., Journal of Structural and Functional Genomics 13 (2012) 241–245.
[58] N. Lamarche, et al., Cell 87 (1996) 519–529.
[59] R.K. Jha, C.E.M. Strauss, Cellular Logistics 2 (2012) 69–77.
[60] S. Narumiya, et al., Cancer Metastasis Reviews 28 (2009) 65–76.
[61] A. Struckhoff, et al., Frontiers in Bioscience 16 (2011) 1915–1926.
[62] T. Mizutani, et al., Cell Motility and the Cytoskeleton 66 (2009) 389–397.
[63] M.F. Olson, E. Sahai, Clinical & Experimental Metastasis 26 (2009) 273–287.
[64] J.J. Bravo-Cordero, et al., Current Biology: CB 21 (2011) 635–644.
[65] L.E. Arias-Romero, J. Chernoff, Biology of the Cell under the Auspices of the European
Cell Biology Organization 100 (2008) 97–108.
[66] L.C. Sanders, Science 283 (1999) 2083–2085.
[67] D. González-Forero, et al., The Journal of Neuroscience: The Ofﬁcial Journal of the
Society for Neuroscience 32 (2012) 68–84.
[68] D.C. Edwards, et al., Nature Cell Biology 1 (1999) 253–259.
[69] A. Arjonen, et al., Cell Adhesion & Migration 5 (2011) 421–430.
[70] J.V. Small, et al., 12 (2002) 112–120.
[71] M. El-Sibai, et al., Journal of Cell Science 120 (2007) 3465–3474.
[72] L.S. Price, et al., Molecular Biology of the Cell 9 (1998) 1863–1871.
[73] I. Kaverina, et al., The International Journal of Biochemistry & Cell Biology 34
(2002) 746–761.
[74] M. Hoffmann, U.S. Schwarz, BMC Systems Biology 7 (2013) 2.
[75] E.A. Cox, A. Huttenlocher, 419 (1998) 412–419.
[76] A. Kwiatkowska, M. Symons, Glioma Signaling 986 (2013) 121–141.
[77] M. El-Sibai, et al., Experimental Cell Research 314 (2008) 1540–1552.
[78] S.P. Palecek, et al., Journal of Cell Science 111 (Pt 7) (1998) 929–940.
[79] E.A. Cox, et al., 12 (2001) 265–277.
[80] B.D. Khalil, M. El-Sibai, Journal of Neuro-Oncology 108 (2012) 333–339.
[81] C. Guilluy, et al., Trends in Cell Biology 21 (2011) 718–726.
[82] M. Symons, J.E. Segall, Genome Biology 10 (2009) 213.
[83] K. Burridge, et al., 116 (2004) 167–179.
[84] F.M. Vega, et al., The Journal of Cell Biology 193 (2011) 655–665.
[85] E.a. Clark, et al., Nature 406 (2000) 532–535.
[86] K. Stengel, Y. Zheng, Cellular Signalling 23 (2011) 1415–1423.
[87] N.S. Sipes, et al., The Journal of Biological Chemistry 286 (2011) 36469–36477.
[88] I. Tatsuno, et al., Progress in Cell Cycle Research 4 (2000) 19–25.
[89] T. Yoshida, et al., Molecular Cancer Therapeutics 9 (2010) 1657–1668.
[90] M. Liberto, et al., Oncogene (2002), http://dx.doi.org/10.1038/sj/onc/1205242.
[91] L.M. McHardy, et al., Molecular Cancer Therapeutics 4 (2005) 772–778.
[92] M. Chatterjee, K.L. Van Golen, International Journal of Cancer. Journal International
Du Cancer 129 (2011) 61–69.
[93] R.a. Patel, et al., Oncogene (2013), http://dx.doi.org/10.1038/onc.2012.634.
